Aktis Oncology (NASDAQ:AKTS) Stock Price Passes Below 50-Day Moving Average – Should You Sell?

Aktis Oncology (NASDAQ:AKTS)’s stock price passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $19.47 and traded as low as $17.19. Aktis Oncology shares last traded at $18.63, with a volume of 540,744 shares.

Analysts Set New Price Targets

A number of research analysts recently weighed in on AKTS shares. Wall Street Zen raised shares of Aktis Oncology to a “hold” rating in a report on Saturday, January 17th. TD Cowen started coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They set a “buy” rating on the stock. Leerink Partners began coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 price objective for the company. Finally, Bank of America assumed coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, Aktis Oncology presently has an average rating of “Buy” and a consensus target price of $31.25.

Aktis Oncology Stock Up 2.5%

The firm has a fifty day moving average of $19.47.

Insider Buying and Selling at Aktis Oncology

In other news, major shareholder Ansbert Gadicke bought 1,112,777 shares of Aktis Oncology stock in a transaction dated Monday, January 12th. The shares were acquired at an average price of $18.00 per share, with a total value of $20,029,986.00. Following the completion of the purchase, the insider owned 10,260,064 shares in the company, valued at $184,681,152. The trade was a 12.17% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ecor1 Capital, Llc bought 2,222,222 shares of the stock in a transaction dated Monday, January 12th. The stock was purchased at an average price of $18.00 per share, with a total value of $39,999,996.00. Following the acquisition, the director directly owned 4,348,658 shares in the company, valued at approximately $78,275,844. The trade was a 104.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 6,117,776 shares of company stock valued at $110,119,968.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.